Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  September 17, 2017

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:apataceptApprovalsClinicaldrugFDAMedicationOrenciaoutcomePsoriatic ArthritisRAResearchRheumatoid arthritisrheumatologySafetysirukumabstudyTreatmenttrial

Effectiveness of Steroid Injections vs. Placebo Evaluated for Knee Pain

Catherine Kolonko  |  September 17, 2017

A two-year study among patients with knee osteoarthritis (OA) showed that steroid injections for knee pain were no more effective than saline injections and actually reduced cartilage volume more than placebo. The study, conducted at Tufts Medical Center in Boston, looked at progression of cartilage loss and change in knee pain after treatment with placebo…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:cartilage lossClinicalJAMAknee osteoarthritisknee painoutcomeplaceboResearchRheumatic Diseaserheumatologyrisksalinesteroid injectiontriamcinolone acetonide

Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2017

Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Drug SafetyFDAFood and Drug AdministrationRheumatoid Arthritis (RA)sirukumab

Glucosamine Supplements Don’t Help Knee or Hip Arthritis Pain

Carolyn Crist  |  August 10, 2017

(Reuters Health)—Oral glucosamine has no more effect than placebo on joint pain, according to a new meta-analysis. The analysis of randomized controlled trials from which data have been made public found that at both three-month and 24-month follow-up points, the supplement had no effect on either hip or knee pain from arthritis. Even sub-groups, such…

Filed under:Drug Updates Tagged with:glucosamine supplementsjoint pain cureoral glucosamineOsteoarthritis Research Society InternationalU.S. National Institute for Health and Care Excellence

Mind-Body Techniques for Pain Management

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Delia Chiaramonte, MD, associate director of education at the Center for Integrative Medicine at the University of Maryland School of Medicine in Baltimore, presented the newest thinking on pain to a gathering of rheumatologists at the ACR’s State-of-the-Art Clinical Symposium in April. She began by explaining that pain is more than nociception. Nociception stimulates nerves to…

Filed under:ConditionsMeeting ReportsPain SyndromesResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)braincentral nervous systemFibromyalgiameditationmindPain ManagementResearchrheumatologyyoga

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

Michele B. Kaufman, PharmD, BCGP  |  June 20, 2017

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdiclofenac sodiumFDAFood and Drug Administrationgeneric drugsKnee Osteoarthritis (OA)OsteoporosisRheumatoid Arthritis (RA)sarilumab

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonePsoriatic ArthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

Centrexion’s Chili-Based Painkiller Offers Relief for 6 Months—Study

Natalie Grover  |  June 14, 2017

(Reuters)—A synthetic version of a medicine traditionally extracted from chili plant relieved knee pain among osteoarthritis patients for up to six months, data showed, bringing Centrexion Therapeutics a step closer to developing a safe and effective analgesic. The drug, designed to be injected at the site of pain, is being developed by the privately-held company…

Filed under:Drug UpdatesOsteoarthritis and Bone Disorders Tagged with:CentrexionChili-Based PainkillerCNTX-4975knee pain

Rocketclips, Inc./shutterstock.com

Tips for Managing Young Adult Rheumatology Patients

Gregory Taylor, MSW, RCSW  |  May 18, 2017

Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…

Filed under:ConditionsPediatric ConditionsPractice Support Tagged with:Association of Rheumatology Professionals (ARP)communicationhealthManagementpatient carePediatricphysician patient relationshippsychosocialRheumatic DiseaserheumatologistrheumatologytransitionTreatment

Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 16, 2017

Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 81
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences